IPA.V - ImmunoPrecise Antibodies Ltd


ImmunoPrecise Enters Agreement to Develop Immune-Contraceptive Vaccines for Wildlife


ImmunoPrecise Announces Expansion into Humanizing Technologies and Platforms



J’aimerais mettre l’accent sur ce passage :

«Nous sommes très satisfaits du succès de notre méthode Rapid Prime chez ces animaux», a déclaré Teri Otto, responsable des services de laboratoire chez ImmunoPrecise. «Nous avons livré un grand nombre de clones de haute qualité à nos clients dans un court laps de temps. Il est extrêmement important de souligner que notre qualité constante et supérieure est cruciale pour la clientèle que nous desservons et l’une des clés pour déverrouiller les nouveaux et Répétez les affaires. "

En gros le succes de ces projets confirme que l’humanisation pourra être effectué à grande échelle avec la méthodologie Rapide Prime qui produit des antibodies 60% plus rapide que la compétition.

C’est un tout nouveau créneau pour IPA et le potentiel de revenue est beaucoup mais beaucoup plus grand que la base d’opération car le marché des drogues fait à partir d’antibodies humanisé est en plein expansion. Nivolumab en est un exemple 2.6 milliards l’an dernier et forcast 12 milliards dans 5 ans.

Source : https://www.forbes.com/sites/brucebooth/2017/05/11/human-antibody-discovery-of-mice-and-phage/2/#6e6c679ed420

Divulgation : Je détiens des actions de IPA


ImmunoPrecise Signs Definitive Agreement With U-Protein


ImmunoPrecise completes acquisition of U-Protein and private placement of $5.25 million

VICTORIA, Aug. 23, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has completed the acquisition of U-Protein Express BV (“U-Protein”) whereby the Company has acquired all of the issued and outstanding shares of U-Protein (the “Transaction”) and complete a non-brokered private placement of $5,250,000 (Cdn) (the “Financing”). This Transaction completes the first strategic acquisition for the Company.

“The completion of the acquisition of U-Protein provides an excellent strategic fit for ImmunoPrecise as it is complementary to our expertise in custom monoclonal antibody production as well as offering an exceptional opportunity to expand our business into the European marketplace,” said Tom D’Ozario, President and CEO. “The combined company will be able to offer an expanded portfolio of services, further diversifying our revenue base and achieve our strategic, long-term business objectives.”

Terms of Definitive Agreement with U-Protein

Under the terms of the Definitive Agreement, the Company has acquired all of the issued and outstanding shares of U-Protein for €6,830,000 (CAD$10,108,400) (the “Purchase Price”), of which (A) €2,734,732 (CAD$4,047,390) was paid in cash on closing, (B) a total of 3,030,503 common shares of the Company were issued on closing, and © €2,047,634 (CAD$3,030,498) in deferred payments over a three (3) year period (the “Deferred Payments”). The Deferred Payments may be made, at the election of the U-Protein shareholder, in cash or by the issuance of up to 3,030,498 common shares over a three-year period. The Purchase price will be paid and/or issued to each shareholder of U-Protein in proportion to their respective shareholding of U-Protein.

As part of the Definitive Agreement, the shareholders of U-Protein were issued a dividend of any cash in U-Protein above €500,000. If the Deferred Payments are not satisfied by the Company, the shareholders of U-Protein will be permitted to repurchase the shares of U-Protein from the Company.

As part of the Definitive Agreement, the three of the principal shareholders of U-Protein have executed on-going management and employment contracts, which include non-solicitation and non-competition clauses as well as performance incentives based on the net profits of U-Protein. The Company also appointed Martin Hessing as a director of the Company.

Private Placement Financing

In conjunction with acquisition of U-Protein, the Company is pleased to announce that it completed a non‐brokered private placement of 5,250,000 shares (each, a “Share”) at a price of $1.00 per Share for gross proceeds of up to $5, 250,000.

All securities issued in connection with the private placement will be subject to restrictions on resale expiring on December 17, 2017. The Company issued finders’ a total of 281,100 common shares and paid a total of $12,000.

Proceeds of the financing were used for the acquisition of U-Protein and will be used for working capital purposes.


ImmunoPrecise Antibodies Reports 2017 Annual Results - Revenues up 39% Over Fiscal 2016

The Company recorded a net loss of $5,383,820 during the year ended April 30, 2017, compared to net income of $151,035 for the year ended April 30, 2016. The net loss is comprised of the $3,887,160 listing expenses recorded on completion of the Reverse Takeover-Over (“RTO”), which is a one-time accounting entry and is not reflective of its ongoing operations. The Company also incurred an operating loss of $1,386,474, which is mostly attributable to non-recurring costs in foundational growth-enabling investments made to pursue strategic initiatives which attracted consulting fees and other one-time costs such as systems development, business development and operational efficiency aimed at configuring the Company for significant future growth.

Je ne suis pas un grand fan des compagnies non-profitables mais dans ce cas-ci, des pertes temporaires étaient à prévoir suite à l’entrée en bourse et le financement de $4.3M en décembre dernier. À partir de maintenant, je m’attend à une amélioration continue des résultats financiers.


ImmunoPrecise announces R&D success using the OmniAb® platform to develop fully human antibodies

VICTORIA, Aug. 29, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), announces the Company is now an approved contract research organization (“CRO”) for developing human monocolonal antibodies using the OmniAb® platform of transgenic mice and rats.

The OmniAb® platform consists of the OmniRat®, OmniMouse® and OmniFlic® transgenic rodents. These rodents are bred to produce highly diversified antibody repertoires for the discovery of fully human antibodies with potentially superior therapeutic efficacy and reduced immunogenicity. The OmniAb® platform is owned by Ligand Pharmaceuticals.

ImmunoPrecise Antibodies has now completed two research and development projects, which allowed the Company to test and optimize its unique and proprietary methodologies, including the Rapid Prime immunization protocol.

These two projects were conducted on behalf of Aptevo Therapeutics (“Aptevo”) of Seattle, Washington and Tizona Therapeutics (“Tizona”) of San Francisco, California. In these projects ImmunoPrecise leveraged the power of its internal antibody development process to develop human monoclonal antibodies for two different cell surface therapeutic targets.

“We are pleased with both the execution and outcome of this recent campaign which generated a large number of unique antibodies that will be evaluated in our ADAPTIRTM bispecific platform,” said Dr. David Bienvenue, Senior Director, Protein Sciences of Aptevo Therapeutics.

“The combined approach gave us a diverse repertoire of antibodies to test in our assays. We were very pleased with the outcome of this development project,” said Dr. Vanessa Soros, Senior Principal Scientist at Tizona Therapeutics.

ImmunoPrecise Antibodies Chief Scientific Officer Dr. Deanna Dryhurst, stated, “These research and development projects allowed us to qualify as an official CRO as well as validate that our methodologies performed exceptionally well. We see increasing demand and interest in human monoclonal antibody development.”



Le client est APVO NASDAQ pour $160k USD


Immunoprecise has operating loss of $857,832 in Q1

2017-09-29 18:07 ET - News Release

Mr. Rob Gamley reports
Immunoprecise Antibodies Ltd. has released its financial results for the first quarter ended July 31, 2017, and has provided a business update. The financial statements and related management’s discussion and analysis (“MD&A”) can be viewed on SEDAR at www.sedar.com.
In the first quarter ended July 31, 2017, the Company focused its resources on a number of growth initiatives by investing in:

The building and opening of new laboratory facilities in early May 2017 to increase operational efficiency and to expand capacity to undertake production of humanized antibody production.
The development of sales and marketing structures and initiatives including outreach activities.
The implementation of enterprise solutions for sales, finance, IT and HR to support core growth of the business and strategic acquisition activity and streamlined its contract administration to maintain and facilitate long term business relationships with its clients.

The Company also initiated research and development activity to expand its core business by the development of humanizing platforms for the production of humanized antibodies.
Further, as part of the Company’s focus to aggressively expand its share of the USD$2.6 billion research and development antibody market, delivering its products and services to academic, diagnostic, biotechnology and pharmaceutical customers globally, the Company entered into a binding agreement to acquire all the outstanding shares of U-Protein B.V. (“UPE”), which was successfully completed the acquisition of UPE on August 22, 2017. As a result of the acquisition, the Company anticipates a positive increase in its revenue and an expanded portfolio of services on a going forward basis.
For the three months ended July 31, 2017 the Company recorded revenue of $591,058 compared to $727,425 during the three months ended July 31, 2016. This reduction in revenue stems from the Company focusing on investments to facilitate long term growth in capacity and margins, expansion in the core business and acquisition activities.
For the three months ended July 31, 2017 the company incurred an operating loss of $857,832 compared to a profit of $148,939 for the same period during the previous year. The operating loss was primarily due to the costs related to the Company continuing to make foundational growth-enabling investments in research and development, management and technical personnel, operational efficiency and measures to improve gross margins, capacity expansion of its laboratory facilities, and strategic acquisition activities. In the second quarter, the Company anticipates that these investments will begin demonstrate that the Company can maximize its return on any growth in revenue.
“It is important to emphasize that strategically, we have made significant growth enabling investments in 2017 and have laid the groundwork for ImmunoPrecise’s immediate and long-term success,” stated Tom D’Orazio, CEO of ImmunoPrecise. "We have increased operational efficiencies, expanded lab capacity, entered the higher margin humanized antibody space, and strengthened our team to help serve our clients demands and grow our business. We see our business inflecting over the coming quarters, specifically as our integration with U-Protein nears completion, thereby expanding our suite of product offerings and opening up Europe for our services on a broader basis."
About ImmunoPrecise Antibodies Ltd.
The Company provides custom antibody engineering and production services and protein expression to support research and development programs at leading pharmaceutical and biotechnology companies, as well as academic research laboratories.
Antibodies are naturally occurring proteins capable of binding to specific target molecules, or antigens. They have been used very widely in research assays, diagnostics, purification, biologics and therapeutics.
The Company operates from state of the art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia which house its tissue culture and molecular facilities as well as an animal care unit, and is a member of the Canadian Council for Animal Care and in association with U-Protein Express B.V. its subsidiary laboratory operation in Life Science Incubator, Utrecht Science Park, Utrecht, the Netherlands.
The services offered to customers include the development of mouse and rat monoclonal and rabbit recombinant monoclonal antibodies against a wide spectrum of antigens, as well as polyclonal antibodies, immunologically based assays, and solutions to challenges faced by clients in antibody related research and development. In addition, cryopreservation services are provided for the storage of valuable biological materials including hybridoma clones, plasmid constructs, and cell lines. The antibodies produced by the Company target a wide variety of environmental, diagnostic and research applications.
The Company employs a highly experienced group of R&D scientists. Over the last 25 years, investments in innovative and proprietary technologies and methods have vastly improved the speed and efficiency of monoclonal and polyclonal antibody production.
We seek Safe Harbor.


J’imagine que ça explique la récente baisse du prix de l’action.

Si le prix descend encore plus, on verra p-e des vendeurs motivés qui vont vendre pour les pertes de fin d’année + les actions du pp deviennent libres fin-décembre…à suivre.

Divulgation : plus de position, liquidé à 1.12$ pour d’autres opportunités d’investissements


ImmunoPrecise to Acquire QVQ Holdings BV and Reports Growth Results

VICTORIA, Oct. 2, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with QVQ Holdings BV (“QVQ”) whereby the Company has agreed to acquire all of the issued and outstanding shares of QVQ (the “Transaction”). Currently, U-Protein Express B.V., a wholly owned subsidiary of the Company owns 37% of the issued and outstanding shares of QVQ.

The addition of QVQ will broaden the portfolio of research services the Company can offer its customers. Additionally, QVQ has an available inventory of both unique and/or patented monoclonal antibodies that are being sold directly to customers.


QVQ is a privately held company based in Utrecht, The Netherlands that performs Contract Research for pharmaceutical, biotech and diagnostic companies. A second area of focus for QVQ is working with Universities and research institutes in Collaboration Agreements to develop new intellectual property in the area of diagnostic imaging products.

QVQ’s core capability is the production of single domain antibodies, which are referred to as VHHs. These single-domain monoclonal antibodies are derived from llamas and other camelids. Due to their small size, they have unique biochemical properties ideal for applications in fast-growing areas such as tumor targeting, companion diagnostics, antibody fragments, and bi-specific antibodies, which drug developers are increasingly interested in applying to disease targets in many areas like oncology, diseases of aging, and infectious diseases. Another benefit of VHH molecules is that they are easily humanized due to their similarity to key regions of human antibodies. QVQ has the capability to humanize these antibodies when they are used for therapeutic applications.

During the fiscal year ended December 31, 2016, QVQ had revenues of €435, 125 (CAD $639,633). For the first of half of fiscal 2017, QVQ has revenues of €364,379 (CAD$ 535,637).

Terms of Transaction with QVQ

Under the binding letter of intent, the Company and QVQ have agreed to negotiate a definitive agreement (the “Definitive Agreement”) whereby the Company will acquire all of the issued and outstanding shares of QVQ for €500,000 (CAD$735,000), of which (A) €100,000 (CAD$147,000) will be paid in cash on closing, and (B) €400,000 (CAD$588,000) will be satisfied by the issuance of common shares of the Company on closing.

The letter of intent also requires that the Chief Executive Officer, Edward Dolk, of QVQ to enter into a two-year management contract, which will include non-solicitation and non-competition clauses. The QVQ shareholders will also be entitled to receive a portion of royalties generated from the commercialization of QVQ molecules licensed to Orthros TR as follows: (i) 50% of any royalties due to and received by QVQ from January 1, 2018 to December 31, 2018; (ii) 30% of any royalties due to and received by QVQ from January 1, 2019 to December 31, 2019; and (iii) 10% if any royalties due to and received by QVQ from January 1, 2020 to December 31, 2010.

The parties will be entitled to carry out due diligence of each other until October 31, 2017. Upon the parties completing due diligence to their reasonable satisfaction, the parties will enter into the Definitive Agreement setting forth the terms and conditions of the Transaction by October 31, 2017. Completion of any transaction with QVQ is subject to a number of conditions, including but not limited to, completion of due diligence, negotiation of definitive agreements in respect of such a transaction, and receipt of any required regulatory and shareholder approvals. A transaction cannot be completed until these conditions are satisfied, and there can be no assurance that a transaction will be completed at all.

Growth Initiatives

The Company reports that the focus on growth initiatives in 2017 has resulted in:

Expansion of commercial opportunities in development of humanized antibodies with two significant therapeutic companies;
Increase in the number of long term service agreements by 49%;
Increase in new customers by 15%
With the expansion into the humanized antibody field and an increase in long term service contracts, the Company believes that it has set the groundwork for sustained long term success.


Not so hidden brag Simb :stuck_out_tongue: pour le 1.12.

Je viens de unload 65% de ma position a 0.87


C’est vraiment de la chance car je ne voulais pas vendre mais j’avais besoin de liquidité pour autre chose. Desfois le timing fait bien les choses. Je ne m’attendais pas non plus à ce que ça baisse autant (avant de lire les états financiers du dernier trimestre).

Cela dit, je crois au potentiel à long terme et je vais certainement rebâtir la position si je peux libérer des liquidités et que le marché m’offre une belle opportunité.


Quelqu’un peut m’expliquer l’avantage compétitif de cette entreprise ? J’ai un ami qui a PhD et qui utilise des anti-corps à tous les jours dans ses recherches mais il me dit que le marché est très bien servi et qu’il existe déjà plusieurs fournisseurs établis.

P.S: Je ne connais rien à ce secteur spécifique de niche

Merci !


IPA s’est historiquement spécialisé dans les anticorps produits avec des lapins et a développé une méthodologie plus rapide et efficace que la compétition (RapidPrime). Ces anticorps sont utilisés dans des projets de recherche et non sur des humains. Le fondateur de l’entreprise est un pionnier dans ce domaine. Je suis cependant incapable d’estimer l’ampleur de cet avantage compétitif.

Du côté des anticorps humanisés (pour utilisation sur des humains), les avantages compétitifs se situent au niveau de la propriété intellectuelle. IPA a accès a de la propriété intellectuelle grâce à un partenaire et peut combiner sa méthodologie RapidPrime à la production d’anticorps humanisés. Pour les grandes compagnies pharmaceutiques, le fait de pouvoir produire et commercialiser un traitement plus rapidement (grâce à un fournisseur d’anticorps plus rapide) peut être très significatif lorsque les ventes du traitement sont des centaines de millions de $ par mois.


Merci,je vais en rediscuter avec mon ami et je vous reviens si il a du feedback


Il y a une startup à Sherbrooke qui fait des anticorps avec des oeufs de poulet (https://ibiosolutions.com/fr/)… Peux-tu lui demander comment un centre de recherche choisit? Il y a des avantages ou des niches pour chaque “source” des anticorps?

Cheers :v:


Est-ce que le PP annoncé au début du mois d’Août est fermé ? je ne vois rien à ce sujet


Oui dans le relevé de presse du 23 août : LIEN

Private Placement Financing

In conjunction with acquisition of U-Protein, the Company is pleased to announce that it completed a non‐brokered private placement of 5,250,000 shares (each, a “Share”) at a price of $1.00 per Share for gross proceeds of up to $5, 250,000.

All securities issued in connection with the private placement will be subject to restrictions on resale expiring on December 17, 2017. The Company issued finders’ a total of 281,100 common shares and paid a total of $12,000.

Proceeds of the financing were used for the acquisition of U-Protein and will be used for working capital purposes.